New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
07:14 EDTHTBXHeat Biologics reports Q2 EPS (44c), consensus (40c)
The company said, "The increase in the loss was primarily attributable to an increase of $160,380 in Research and Development expense, an increase of $658,252 in Clinical and Regulatory expense and an increase of $576,708 in General and Administrative expense."
News For HTBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
08:11 EDTHTBXHeat Biologics commences patient dosing of vesigenurtacel-L Phase 2 study
Heat Biologics announced that it has initiated patient dosing in its Phase 2 clinical trial of vesigenurtacel-L, or HS-410, in subjects with high-risk, non-muscle invasive bladder cancer. Vesigenurtacel-L is Heat's investigational drug in a series of proprietary Immune Pan Antigen Cytotoxic Therapy, or ImPACT, based allogeneic cell lines designed to direct killer T cells to attack cancer. The primary endpoint for the Phase 2 portion of the bladder cancer study is one-year disease-free survival. The multi-center Phase 2 portion of Heat's bladder cancer study is designed to determine whether vaccination with one of two doses of vesigenurtacel-L in combination with Bacillus Calmette-Guérin, or BCG, after transurethral resection of bladder tumor, or TURBT, increases disease-free survival at one year compared to BCG in combination with placebo. The blinded, randomized placebo-controlled study will enroll approximately 75 patients. Heat expects to complete patient enrollment of the Phase 2 study in 3Q15 and report topline results in 3Q16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use